Wall Street ends higher but biotech selloff weighs

A trader works on the floor of the New York Stock ExchangeBy Angela Moon NEW YORK (Reuters) – U.S. stocks ended up on Friday but off their session highs as a late afternoon selloff in the biotechnology sector weighed on the overall market. The Nasdaq Composite Index fell nearly 3 percent for the week, marking its worst week since October 2012. The three major U.S. stock indexes had been significantly higher in most of the morning and early afternoon trade following comments from China's Premier Li Keqiang indicating that the country's government was ready to take steps to support its slowing economy. But a 2.8 percent drop in the Nasdaq biotechnology index led the major indexes to session lows.

Canada to remove foreign investment limit on Nordion

Canada's Finance Minister Oliver speaks during Question Period in the House of Commons on Parliament Hill in OttawaOTTAWA/WINNIPEG (Reuters) – The Canadian government will remove the 25-percent foreign investment cap on medical isotope provider Nordion Inc in cases that are deemed to be of net benefit to Canada, under legislation introduced on Friday. "The foreign ownership restrictions with respect to the company were put in place when it was privatized in the early 1990s, and do not serve an ongoing purpose," said Melissa Lantsman, spokeswoman for Finance Minister Joe Oliver. "The removal of the foreign ownership restrictions will allow Nordion to access more investment capital, enabling it to better grow and create jobs, but is conditional on approval of a transaction under the Investment Canada Act." Nordion shares were down slightly in Toronto and New York in late Friday trading.

U.S. FDA moves to offset shortage of common saline solution

(Reuters) – Moving to offset shortages of a common saline used in hospitals and dialysis centers, the U.S. Food and Drug Administration said on Friday that it will temporarily allow Fresenius Kabi USA LLC to distribute normal saline from its manufacturing facility in Norway. The FDA said the initial shipments would help but not resolve shortages of 0.9 percent sodium chloride injection, also known as normal saline. The FDA said it is continuing to work with Baxter Healthcare Corp, B.Braun Medical Inc. and Hospira Inc to restore their supplies to hospitals and health clinics.

Pot-smoking style linked to addiction risk

An attendee holds out several marijuana buds at the High Times U.S. Cannabis Cup in SeattleBy C.E. Huggins NEW YORK (Reuters Health) – Marijuana smokers' behavior is more important than the potency of their pot or how much of the psychoactive ingredient THC they take in for predicting who will become dependent, according to a small new study. Researchers have debated whether smokers of high-potency cannabis varieties are at greater risk of addiction because they get more THC, or if they compensate for the pot's strength by using or inhaling less of it. But it's their style of pot smoking that predicted who was most likely to become dependent. Most previous research into cannabis dependence has looked mainly at how frequently a person uses cannabis, Van der Pol and her team note in the journal Addiction.

Massachusetts bans sale of FDA-approved Zogenix painkiller

Criticism of painkiller Zohydro intensifiesBy Susan Heavey WASHINGTON (Reuters) – Officials in Massachusetts have blocked sales of Zogenix's controversial but U.S.-approved painkiller Zohydro, prompting the drugmaker to criticize what it called an "unprecedented action." The state's ban "only serves to unfairly restrict patient access," the company said in a statement late Thursday. Massachusetts Governor Deval Patrick announced the Zohydro ban in a speech on Thursday, formally declaring a public health emergency stemming from the abuse of opioids in the New England state. Bradley Galer, chief medical officer of Zogenix, said Massachusetts officials are misguided about Zohydro's potency and dosage, and noted that other painkillers without abuse-resistant technologies are already on the U.S. market. The drug has since come under further scrutiny from members of Congress, dozens of state attorney generals, medical groups and drug treatment experts seeking to block the drug even as the FDA's top official has defended its action.

1 13 14 15 16 17 104